UT-OWLET
Owlet, Inc. (“Owlet” or the “Company”) (NYSE:OWLT), the pioneer of smart infant monitoring, announced today at Kind + Jugend in Cologne, Germany, that medically-certified Dream Sock will soon be available in even more countries, including Poland, Greece, and the Czech Republic. Dream Sock is the Company’s medically-certified baby monitor accessible across Europe, giving parents safe and accurate health readings and actionable alarms while their baby sleeps.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240903971490/en/
Owlet Dream Sock (Photo: Business Wire)
“Dream Sock has already made a huge impact on thousands of families since its global launch a few months ago, and we are eager to continue the roll-out of our medical-grade technology to even more parents,” said Kurt Workman, Owlet Chief Executive Officer and Co-Founder. “We are attending Kind + Jugend this week to meet with current and potential distribution partners to demonstrate our latest technology and show the impact Owlet is having across the world.”
Dream Sock is CE and UKCA Marked under EU and UK Medical Device Regulations and meets rigorous regulatory standards, ensuring its safety, efficacy, and compliance with all applicable requirements. This smart digital health infant monitoring device comfortably wraps around Baby's foot, providing real-time monitoring of pulse rate, oxygen saturation level, sleep patterns, and more. The connected Owlet Dream App (available on iOS and Android) delivers live health readings directly to mobile devices and the included Base Station – both of which will immediately notify users if Baby has low/high pulse rate, or low oxygen. It is clinically proven to accurately track and display an infant’s vital signs and is intended for healthy infants between 0-18 months and 2.5-13.6 kg. Dream Sock can also be paired with the Owlet Cam® 2 allowing caregivers to see and hear Baby from anywhere, receive motion notifications, and more.
Dream Sock is available now for purchase in the UK and select European markets. Dream Sock will be available in the following markets via Owlet’s localized websites and key retailers in the coming weeks: Poland, the Czech Republic, Slovakia, Hungary, Romania, Bulgaria, and Greece.
About Owlet, Inc.
Owlet’s digital health infant monitoring platform is transforming the journey of parenting. The Company (NYSE:OWLT), a small-cap healthcare growth equity, offers FDA-authorized medical and consumer pediatric wearables and an integrated HD visual and audio camera that provide real-time data and insights to parents who safeguard health, optimize wellness, and ensure peaceful sleep for their children.
Since 2012, over 2 million parents worldwide have used Owlet’s platform contributing to one of the largest collections of consumer infant health and sleep data. The Company continues to develop software and digital data solutions to bridge the current healthcare gap between hospital and home and bring new insights to parents and caregivers globally. Owlet believes that every child deserves to live a long, happy, and healthy life. To learn more, visit www.owletcare.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the “Reform Act”). All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding the Company’s certification and launch of its Dream Sock in the European Market and the impacts, growth prospects, and expanded product offerings and product availability in international markets. In some cases, you can identify forward-looking statements by terms such as “estimate,” “may,” “believes,” “plans,” “expects,” “anticipates,” “intends,” “goal,” “potential,” “upcoming,” “outlook,” “guidance,” the negation thereof, or similar expressions, although not all forward-looking statements contain these identifying words. Forward-looking statements are based on the Company’s expectations at the time such statements are made, speak only as of the dates they are made and are susceptible to a number of risks, uncertainties and other factors. For all such forward-looking statements, the Company claims the protection of the safe harbor for forward-looking statements contained in the Reform Act. The Company’s actual results, performance or achievements may differ materially from any future results, performance or achievements expressed or implied by our forward-looking statements. Many important factors could affect the Company’s future results and cause those results to differ materially from those expressed in or implied by the Company’s forward-looking statements. Such factors include, but are not limited to, (i) the availability of, adoption and commercial success of Dream Sock and its new medical technology within additional international markets, (ii) the regulatory pathway for the Company’s products, including submissions to, actions taken by and decisions and responses from regulators, such as the FDA and similar regulators outside of the United States, as well as the Company’s ability to obtain and maintain regulatory approval or certification for our products and other regulatory requirements and legal proceedings; (iii) any developments in litigation in which the Company is involved, including the Butala and Cherian cases described in the Company’s reports filed with the U.S. Securities and Exchange Commission (the “SEC”); (iv) the ability of the Company to maintain listing of its Class A common stock on a national stock exchange, including by coming back into compliance with Section 802.01B of the NYSE Listed Company Manual within the allotted cure period described in the Company’s reports filed with the SEC; (v) the Company’s competition and the Company’s ability to profitably grow and manage growth; (vi) the Company’s ability to enhance future operating and financial results or obtain additional financing to continue as a going concern; (vii) risks associated with the Company’s current loan and debt agreements, including compliance with debt covenants, restrictions on the Company’s access to capital, the impact of the Company’s overall debt levels and the Company’s ability to generate sufficient future cash flows to meet the Company’s debt service obligations and operate its business; (viii) the ability of the Company to implement strategic initiatives, reduce costs, grow revenues, develop and launch new products, innovate and enhance existing products, meet customer demands and adapt to changes in consumer preferences and retail trends; (ix) the Company’s ability to acquire, defend and protect its intellectual property and satisfy regulatory requirements, including but not limited to requirements concerning privacy and data protection, breaches and loss, as well as other risks associated with the Company’s digital platforms and technologies; (x) the Company’s ability to maintain relationships with customers, manufacturers and suppliers and retain Owlet’s management and key employees; (xi) the Company’s ability to upgrade and maintain its information technology systems; (xii) changes in applicable laws or regulations; (xiii) the impact of and disruption to the Company’s business, financial condition, operations, supply chain and logistics due to economic and other conditions beyond the Company’s control, such as health epidemics or pandemics, macro-economic uncertainties, social unrest, hostilities, natural disasters or other catastrophic events; (xiv) the possibility that the Company may be adversely affected by other economic, business, regulatory, competitive or other factors, such as changes in discretionary consumer spending and consumer preferences; and (xv) other risks and uncertainties set forth in the Company’s other releases, public statements and filings with the SEC, including those identified in the “Risk Factors” section of the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023, subsequent Quarterly Reports on Form 10-Q, and any current or periodic reports filed with the SEC. All such forward-looking statements attributable to the Company or any person acting on the Company’s behalf are expressly qualified in their entirety by the cautionary statements contained or referred to above. Moreover, the Company operates in an evolving environment. New risk factors and uncertainties may emerge from time to time, and factors that the Company currently deems immaterial may become material, and the Company can't predict such events or how they may affect the Company. Except as required by law, the Company assumes no obligation to update any forward-looking statements after the date of this press release, whether because of new information, future events or otherwise, although the Company may do so from time to time. The Company does not endorse any projections regarding future performance that may be made by third parties.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240903971490/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Australian Defence Force Secures Satellite Communications on SES IS-2212.1.2026 22:30:00 CET | Press release
New agreement for uninterrupted UHF connectivity for Australian Defence Force through 2033, With Options Extending to 2041 Satellite communications solutions provider SES will provide secure uninterrupted satellite communications to the Australian Defence Force (ADF) for a minimum of 16 years thanks to a new extended agreement. The service will be provided via the SES Intelsat 22 satellite and an ultra-high frequency (UHF) military communications payload. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260112137182/en/ Assistant Secretary Space Systems Branch, Michael Hunt, formalizes contract negotiations for the through-life support of the IS-22 satellite with Rory Welch, senior vice-president of service delivery at SES Space and Defense. Photos: Corporal Annika Smit Under the renewed arrangement, SES will reposition the IS-22 satellite to a new orbital slot specified by the ADF, continuing a mission that has been the corne
NetApp Appoints Paul Fipps to the Board of Directors12.1.2026 22:05:00 CET | Press release
NetApp® (NASDAQ: NTAP), the intelligent data infrastructure company, today announced that Paul Fipps, President of Global Customer Operations at ServiceNow, has joined its Board of Directors. The board now has ten directors, nine of whom are independent, and 50% of whom have been appointed within the last five years. Fipps brings more than 20 years of experience driving technology-enabled growth and customer transformation. At ServiceNow, he currently leads global sales, customer success, partner ecosystems, and field operations. He previously served as EVP of Worldwide Sales at ServiceNow and as President of Under Armour Connected Fitness and Chief Experience Officer at Under Armour, overseeing global direct-to-consumer, connected fitness, and digital experiences. He also previously served on the advisory board of Quantum Metric. Fipps holds a B.S. in Information Systems, an MBA from the University of Baltimore, and is a graduate of The Wharton School’s Advanced Management Program. “P
FDA Accepts New Drug Application for Pimicotinib for the Treatment of Tenosynovial Giant Cell Tumor12.1.2026 20:00:00 CET | Press release
Not intended for Canada-, UK- or US-based media Merck, a leading science and technology company, announced today that the U.S. Food and Drug Administration (FDA) has accepted the company’s new drug application (NDA) for pimicotinib as a systemic treatment for patients with tenosynovial giant cell tumor (TGCT). The application is based on the primary results and longer-term follow-up of the global Phase 3 MANEUVER study, which demonstrated deep and durable tumor responses and meaningful improvements in clinical outcomes with pimicotinib. “With pimicotinib, we have an opportunity to significantly advance care for people living with TGCT, a painful and debilitating disease that has few effective and well-tolerated treatment options beyond surgery,” said David Weinreich, Global Head of R&D and Chief Medical Officer for the Healthcare business of Merck. “Based on clinical trial results showing not only a reduction in tumor burden, but also the ability to help alleviate symptoms like pain an
Fabentech receives Marketing Authorization for Ricimed®, an antidote against ricin poisoning12.1.2026 19:32:00 CET | Press release
First Marketing Authorization granted in France for the treatment of ricin poisoning, one of the most toxic natural substances in the world and a recognized priority biological threat. Ricimed® addresses a previously unmet medical need in the management of severe and potentially fatal ricin intoxications.Supported by the French Ministry of the Armed Forces and Veterans Affairs (the Directorate General of Armaments and the French Military Health Service), the development of Ricimed® illustrates Fabentech’s transition to a new scale and, with recent support from the European HERA Invest program, reinforces its positioning as a reference player in medical countermeasures against biological threats, serving both civilian and military markets. Fabentech, a French biopharmaceutical company specializing in medical countermeasures against biological threats, today announces that it has been granted Marketing Authorization for Ricimed®, a treatment for ricin poisoning. This press release featur
Traxys Group and the Shareholders of Comax2 AB - the holding company of Carbomax AB - sign Share Purchase Agreement to sell 100% interests to Traxys Group12.1.2026 19:20:00 CET | Press release
Traxys S.à.r.l., Investment Aktiebolaget Spiltan and other major shareholders of Comax 2 AB – the holding company of Carbomax AB –are pleased to announce that they have signed a Share Purchase Agreement (SPA) to sell 100% interests to Traxys Group. Carbomax AB is a leading Swedish trading house and industrial operator specializing in ferroalloys, carbon products and briquettes. The transaction aims to strengthen Traxys’ presence in the Scandinavian market and support the region’s transition toward sustainable steel production. Closing of the transaction is expected to occur in the first quarter 2026 following clearance by Swedish authorities, including foreign direct investment and antitrust approvals. Carbomax serves regional steel plants and most of foundries across the Nordics. With its strategic location near Västerås harbor and integrated processing capabilities Carbomax is well-positioned to capitalize on growing demand for green steel and sustainable raw materials. Mark Kristoff
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
